Newsroom
  • Press Releases
  • Presentations
Investors
  • Overview
  • Warrant Exercise Inquiries
  • Restricted Stock Inquiries
  • Notice to Stockholders
  • News / Events
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
Clinical Trial Enrollment
  • Triple-Negative Breast Cancer
  • COVID-19 Mild to Moderate
  • COVID-19 Severe or Critical
Contact

CytoDyn Inc.

  • Home
  • About CytoDyn
    • Meet CytoDyn
  • Our Science
  • Pipeline
    • Overview
    • HIV
    • Cancer
    • GVHD
    • COVID-19
  • Expanded Access
  • Our Team
    • Management Team
    • Board of Directors
  • Careers
    • Now Hiring
  • Scientific Board of Advisors
  • Newsroom
  • Investors
  • Clinical Trial Enrollment
  • Contact
Latest News

FOR THE LATEST DEVELOPING NEWS Click Here

Hospitals Enrolling COVID-19 Severe-to-Critical

Investment Community Webcast on Monday, March 8

Antibody-based strategies in HIV therapy

Dr. Seethamraju’s Presentation at Special isirv-AVG Virtual Conference

Manuscript Accepted by Infectious Diseases Society of America

Into the Looking Glass: Post-Viral Syndrome Post COVID-19

EUA for COVID-19 Vaccines and Treatments in the Philippines

Leronlimab’s Mechanism of Action in COVID-19 Published

Leronlimab role in COVID-19

Experimental Drugs Aim to Treat Long-Haul Covid Patients

Research on Critically Ill COVID-19 Patients Published in Journal of Translational Autoimmunity

Leronlimab and Long-Haulers

Latest Publication Leronlimab Blocks Breast Cancer

CytoDyn Q&A with CEO Nader Pourhassan - January 26

Press Releases

Newsroom

Newsroom

  • Press Releases
  • Presentations

CytoDyn Releases Mechanism of Action Animation for Leronlimab in Immuno-Oncology

Jul 02, 2020 6:00am EDT

CytoDyn and NIH of Mexico Complete Memorandum of Understanding to Conduct Small Covid-19 Phase 3 Trial for Severe and Critically Ill Patients

Jun 29, 2020 6:00am EDT

CytoDyn Initiates Phase 2 Clinical Trial With Leronlimab for Treatment of NASH

Jun 11, 2020 6:59pm EDT

CytoDyn Reached Its Enrollment Target for Phase 2 COVID-19 Trial for Mild to Moderate Indication – Primary End Point Announcement Is Next

Jun 11, 2020 4:05pm EDT

Drs. Pourhassan and Kelly of CytoDyn to Hold Conference Call to Provide Updates on COVID-19 Phase 2 and 3 Trials, NASH, BLA for HIV and Manufacturing of Leronlimab in 2020-2021

Jun 09, 2020 6:00am EDT

CytoDyn Receives BLA Acknowledgment Letter From the FDA

Jun 08, 2020 6:00am EDT

CytoDyn to Present at Wall Street Reporter’s Livestream Event on June 2, 2020 at 12:30 pm ET / 9:30 am PT

Jun 01, 2020 6:15am EDT

CytoDyn Files Request With FDA for Priority Review of BLA for First Approval

Jun 01, 2020 6:00am EDT

CytoDyn to Hold Conference Call to Provide Updates on COVID-19 (Phase 2, 3 & eIND), Cancer (mTNBC, Phase 2 for 22 Solid Tumor Cancers), HIV (BLA, Monotherapy), NASH, GvHD and MS

May 22, 2020 8:49pm EDT

CytoDyn and the Mexican National Institutes of Health Participate in a Collaborative Study of Leronlimab for the Treatment of Severe/Critical COVID-19 Population

May 19, 2020 6:00am EDT
RSS
  • Prev
    • 1...
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • ...33
    Next
    © 2021 CytoDyn Inc. All Rights Reserved.
    • Twitter
    • Facebookj
    Privacy Policy Disclaimer Sitemap